Becaplermin topical
Indications
Becaplermin topical is used for:
Diabetic Neuropathic Ulcers
Adult Dose
Diabetic Neuropathic Ulcers
Indicated for treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply; use adjunctively to, and not a substitute for, good ulcer care practices including initial sharp debridement, pressure relief, and infection control
Amount to be applied will vary depending upon size of ulcer area
Formula in inches per tube size
15 g tube: Length of ulcer × width × 0.6 = Length of gel (inches)
2 g tube: Length of ulcer × width × 1.3 = Length of gel (inches)
Formula in centimeters per tube size
15 g tube: Length of ulcer × width ÷ 4 = Length of gel (cm)
2 g tube: Length of ulcer × width ÷ 2 = Length of gel (cm)
Child Dose
Renal Dose
Administration
Topical Administration
Squeeze calculated length of gel onto clean surface, then spread evenly over ulcer using cotton swab, tongue depressor or similar implement
Cover gel with saline-moistened dressing for 12 hr; then rinse off residual gel with saline and apply new saline-moistened dressing (no gel)
Remeasure ulcer weekly or biweekly to adjust dosage
If ulcer size not decreased 30% in 10 weeks, or not healed in 20 weeks, reassess continued treatment with becaplermin
Contra Indications
Hypersensitivity
Neoplasm at application site
Precautions
Malignancies distant from the site of application have occurred in patients using becaplermin gel a clinical study and in postmarketing use contains becaplermin, a recombinant human platelet-derived growth factor, which promotes cellular proliferation and angiogenesis; evaluate benefits and risks before prescribing in patients with known malignancy
If application site reactions occur, the possibility of sensitization or irritation caused by parabens or m-cresol should be considered; consider interruption or discontinuation and further evaluation (eg, patch testing) according to clinical circumstances
Pregnancy-Lactation
Pregnancy
No data are available
Animal reproduction studies have not been conducted
Lactation
No data are available; developmental and health benefits of breastfeeding should be considered along with the lactating woman’s clinical need for the drug and any potential adverse effects on the breastfed child from becaplermin
Interactions
Adverse Effects
Side effects of Becaplermin topical :
1-10%
Erythema
Skin rash
<1%
Ulcer infection
Tunneling of ulcer
Skin ulceration
Local pain
Mechanism of Action
Recombinant human platelet-derived growth factor; promotes chemotactic recruitment and proliferation of cells involved in wound repair and enhances granulation tissue formation